COP
56
-6
DTE
59
3
SRE
49
-3
MAS
54
-5
CME
61
-4
BRK.B
50
-6
LLY
54
-5
WFC
58
-3
KLAC
57
3
HPQ
63
6
GT
50
-2
TDC
62
2
JCI
47
-2
COF
62
2
ACN
34
-4
SYF
81
7
ESS
59
3
FE
48
2
AAPL
49
3
HD
35
6
COP
56
-6
DTE
59
3
SRE
49
-3
MAS
54
-5
CME
61
-4
BRK.B
50
-6
LLY
54
-5
WFC
58
-3
KLAC
57
3
HPQ
63
6
GT
50
-2
TDC
62
2
JCI
47
-2
COF
62
2
ACN
34
-4
SYF
81
7
ESS
59
3
FE
48
2
AAPL
49
3
HD
35
6
Financhill
Back

NovaBay Pharmaceuticals 10K Form

Sell
10

NBY
NovaBay Pharmaceuticals

Last Price:
0.07
Seasonality Move:
-10.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NBY News And Ratings

See the #1 stock for the next 7 days that we like better than NBY

NBY Financial Statistics

Sales & Book Value

Annual Sales: $14.73M
Cash Flow: $-316K
Price / Cash Flow: 0
Annual Sales: $0.12
Price / Book: 1.71

Profitability

EPS (TTM): -3.30650
Net Income (TTM): $-9.64M
Gross Margin: $7.9M
Return on Equity: -125.66%
Return on Assets: -69.74%

NovaBay Pharmaceuticals Earnings Forecast

Key NovaBay Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 21 years for NBY is 53.61%.
  • The Selling, General & Administrative Expenses for NBY have been equal to 87.12% of Gross Profit Margin.
  • The Research & Development expenses have been 0.46% of Revenue.
  • The Net Earning history of NBY is -65.46% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 11 years.

NovaBay Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: NBY
CUSIP: 66987P
Website: novabay.com

Debt

Debt-to-Equity Ratio: 0.34
Current Ratio: 1.67
Quick Ratio: 0.91

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 3.09

NBY Technical Analysis vs Fundamental Analysis

Sell
10
NovaBay Pharmaceuticals (NBY) is a Sell

Is NovaBay Pharmaceuticals a Buy or a Sell?